Li, Hao
Agrawal, Sumit
Rohani, Seyed Alireza
Zhu, Ning
Cacciabue, Daniela I.
Rivolta, Marcelo N.
Hartley, Douglas E. H.
Jiang, Dan
Ladak, Hanif M.
O’Donoghue, Gerard M.
Rask-Andersen, Helge
Funding for this research was provided by:
Uppsala University
Article History
Received: 15 June 2022
Accepted: 11 October 2022
First Online: 8 November 2022
Competing interests
: Marcelo N. Rivolta is the Founder and Chief Scientific Officer of Rinri Therapeutics. All other authors have no competing/conflict of interest.